Agios Pharmaceuticals (AGIO) Current Deferred Revenue (2012 - 2022)

Agios Pharmaceuticals' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $2.5 million for Q1 2022.

• Quarterly Current Deferred Revenue changed N/A year-over-year to $2.5 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $2.5 million (changed N/A YoY) and the FY2019 annual result came in at $61.5 million, up 88.06% from the prior year.
• Current Deferred Revenue was $2.5 million for Q1 2022 at Agios Pharmaceuticals, up from $306000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $61.5 million in Q4 2019 and bottomed at $306000.0 in Q1 2020.
• A 4-year average of $24.4 million and a median of $22.2 million in 2019 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2019 — Current Deferred Revenue surged 2852.64% — and 2020, when it sank 98.62%.
• Agios Pharmaceuticals' Current Deferred Revenue stood at $32.7 million in 2018, then jumped by 88.06% to $61.5 million in 2019, then sank by 99.5% to $306000.0 in 2020, then surged by 716.99% to $2.5 million in 2022.
• Business Quant data shows AGIO's Current Deferred Revenue at $2.5 million in Q1 2022, $306000.0 in Q1 2020, and $61.5 million in Q4 2019.